Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus letrozole as neoadjuvant therapy for HR-positive/HER2-negative breast cancer
ChiCTR2600131806Phase 2Recruiting
- Sponsor
- Weifang People's Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib and letrozole in breast cancer, sponsored by Weifang People's Hospital. Primary endpoint: Complete cell cycle arrest rate. Started Sep 2025; status: recruiting.
02
Drugs
dalpiciclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600131806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131806.